Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Bowen Yang is reportedly leaving 'Saturday Night Live' after this week's episode - 2What's Your Number one Superhuman Film Made?
- 3How to see the Ursids, the final meteor shower of 2025
- 4Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- 5Finding China: Four Urban areas for a Remarkable Excursion
- The Force of Mentorship: Self-improvement through Direction
- The beauty advent calendar boom is here. Sephora kids are all in.
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- Oldest evidence of human fire-making discovered at site in England
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
